Compare EPAM Systems Inc (EPAM) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Zimmer Biomet Holdings Inc — how do they compare? EPAM Systems Inc trades at $85.82 (market cap $4.49B), while Zimmer Biomet Holdings Inc trades at $93.25 (market cap $17.44B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3.9× EPAM Systems Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals.
| EPAM | ZBH | |
|---|---|---|
Market Cap | $4.49B | $17.44B |
Sector | Technology | Health |
52-Week High | $221.40 | $107.71 |
52-Week Low | $76.04 | $79.58 |
Enterprise Value | $3.74B | $24.49B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $87.22, up 3.22% today, with strong analyst support (65% buy ratings) and a consensus price target of $128.55 suggesting 47% upside. The stock shows attractive valuation metrics with P/E of 12.35 and P/S of 0.86, though technical indicators signal bearish momentum. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $2.86 exceeding expectations by $0.11. The company maintains solid profitability with 6.96% net margin and 10.93% ROE.
EPAM presents a compelling value opportunity with significant upside potential based on analyst targets, though near-term technical weakness and recent index reclassification from S&P 500 to SmallCap 600 create headwinds. The company's AI transformation expertise and strong client partnerships position it for growth, but investors should monitor execution risks and competitive pressures in the IT services sector.
Zimmer Biomet (ZBH) trades at $91.03, down 3.24% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue growth has climbed from $6.9B in 2022 to $8.2B in 2025, though net income margin dipped to 8.56%. Recent corporate developments include a $140M acquisition and expansion in India, supporting long-term growth initiatives.
The outlook remains cautiously optimistic with a consensus price target of $97.67, implying 7% upside. Key opportunities include operational efficiency and market share gains, while risks involve debt levels rising to 32.57% of assets and competitive pressures in medical technology. Earnings on August 5 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
